Genedrive EBIT per Share
The EBIT per Share of Genedrive (GDR.L) as of Aug 10, 2026 is -0.01 GBP. In the previous year, EBIT per Share was -0.04 GBP — a change of -72.75% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.01GBP
YoY
-72.75%
Last updated:
EBIT per Share of Genedrive is 2026 -0.01 GBP. EBIT per Share of Genedrive was 2025 -0.04 GBP. It decreases by -72.75% higher compared to the previous year.
Access this data via the Eulerpool API
Genedrive Stock analysis
What does Genedrive do? Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013.
The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests.
The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences.
Some of Genedrive's key products include:
- Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy.
- Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes.
- Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences.
The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions.
In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance.
Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future. Genedrive is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Genedrive stock
EBIT per Share of Genedrive is -0.01 GBP in 2026.
EBIT per Share of Genedrive changed from -0.04 GBP to -0.01 GBP, representing a -72.75% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Genedrive since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Genedrive
All Key Metrics — Genedrive
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth